Section one: Contracting authority
one.1) Name and addresses
Business Energy and Industrial Strategy
1 Victoria Street
London
SW1H0ET
Country
United Kingdom
Region code
UKI32 - Westminster
Justification for not providing organisation identifier
Not on any register
Internet address(es)
Main address
https://www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy
one.4) Type of the contracting authority
Ministry or any other national or federal authority
one.5) Main activity
General public services
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Supply agreement SARS-CoV-2 mRNA Vaccine
two.1.2) Main CPV code
- 33651600 - Vaccines
two.1.3) Type of contract
Supplies
two.1.4) Short description
The procurement of the mRNA-1273 vaccine.
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £1
two.2) Description
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The procurement of the mRNA-1273 vaccine.
two.2.5) Award criteria
Price
two.2.11) Information about options
Options: No
two.2.14) Additional information
Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors .
Contract end date is being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). The contract end date is variable based on production and delivery of the requirement. There are significant challenges to overcome and the end date may not be a true reflection, setting unrealistic expectation for the public and in the market. Provision of the contract term may provide valuable information to competitors that may impact negotiations or future competition in the market.
Sub-contractor details are being withheld on grounds that release of the information would be contrary to public interest under Regulation 50(6)(a). This information is very sensitive given potential for targeting and disruption of the activities at the facilities which would be contrary to public interest as these activities are critical to success and delivery of the requirement.
Please see linked the original notice published on Contracts Finder:
https://www.contractsfinder.service.gov.uk/Notice/8930d6c5-354d-44d0-8540-c134fe59aa0a
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Award of a contract without prior publication of a call for competition in the cases listed below
- Extreme urgency brought about by events unforeseeable for the contracting authority
Explanation:
The award of the contract to Moderna is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)).
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
30 November 2021
five.2.2) Information about tenders
Number of tenders received: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Moderna Switzerland GmbH
Aeschenvorstadt 48
Basel
4051
Country
Switzerland
NUTS code
- CH - Switzerland
Moderna Switzerland GmbH
Company Number: CHE-344.522.989
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £1
Total value of the contract/lot: £1
Section six. Complementary information
six.4) Procedures for review
six.4.1) Review body
Department for Business, Energy and Industrial Strategy
London
Country
United Kingdom